Distillery lobbyists came to fight, bearing samples.
The higher incidence of CTCs bearing putative stem cell and EMT traits in metastatic disease, suggests that these characteristics may prevail on CTCs during disease progression.
Accordingly, CTCs bearing characteristics of an EMT phenotype should be actively involved in tumour dissemination, proliferation and metastasis.
Patients P1, P2, and P4 had similar CTC profiles characterized by various stages of ploidy and the presence of highly aneuploid cells, while patient P3 had less CTCs bearing high ploidy.
In the current study, CTCs bearing high ALDH1 expression, along with nuclear TWIST localization, are not proven to be cancer stem cells undergoing EMT.
We show that qualitative and quantitative analysis of CTCs bearing ROS1 abnormalities is possible in ROS1-rearranged patients undergoing ROS1-inhibitor therapy.
Among 70 cfDNA and 39 CTC samples of overt myeloma samples (newly diagnosed or relapsed), there were 76%, 41%, and 24% of cfDNA samples with ≥3%, 5%, and 10% tumor fractions, respectively (Fig. 1c, blue panel).
MM_2205 CTC sample used 0.7 power due to lower coverage.
30/31 (96.8%) samples had at least 1 CTC, 15/31 (48.4%) samples at least 10 CTCs, with CTC total counts ranging from 0.1 to 9.67 CTCs/mL of blood (Table 1, Fig. 2B).
We applied our integrated workflow to 107 cfDNA samples and 56 CTC samples with different stages of disease progression.
For instance, a TP53 subclone was only detected in cfDNA and CTCs in sample MM_2017 (Fig. 5a, c and Fig. 6a, c).
